密歇根大学研究人员确认CDK12基因突变导致前列腺癌呈攻击性,开发口腔降解器,针对CDK12和CDK13进行可能的临床试验。 University of Michigan researchers identify CDK12 gene mutation driving aggressive prostate cancer, develop oral degrader targeting CDK12 and CDK13 for potential clinical trials.
密歇根大学Rogel癌症中心的研究人员发现CDK12基因突变,导致前列腺癌呈攻击性。 Researchers at the University of Michigan Rogel Cancer Center have identified a mutation in the CDK12 gene that drives aggressive prostate cancer. 他们研制了一种口腔降压器,针对的是CDK12和相关的CDK13基因,在实验室测试中显示出抑制肿瘤生长的希望。 They developed an oral degrader targeting CDK12 and the related CDK13 gene, showing promise in lab tests for halting tumor growth. 这种治疗仍处于临床前阶段,计划将其推进临床试验,如果结合现有的疗法,可能会加强治疗。 This treatment is still in the pre-clinical stage, with plans to advance it toward clinical trials, potentially enhancing treatment when combined with existing therapies.